Post-License Safety Evaluation of Influenza Virus Vaccine
Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine
Sponsor: China National Biotec Group Company Limited
Listed as NCT02136017, this observational or N/A phase trial focuses on Adverse Drug Event and Influenza and remains completed. Sponsored by China National Biotec Group Company Limited, it has been updated 6 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Apr 2018 — Jan 2021 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- China National Biotec Group Company Limited
- Sichuan Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.